67 related articles for article (PubMed ID: 22595946)
1. Development of a computerized morphometry application for assessment of the tumor fraction in colon carcinoma tissue samples.
Hershkovitz T; Shenhav A; Sabo E; Ben-Izhak O; Hershkovitz D
Appl Immunohistochem Mol Morphol; 2013 Jan; 21(1):54-8. PubMed ID: 22595946
[TBL] [Abstract][Full Text] [Related]
2. Two initiation sites of early detection of colon cancer, revealed by localization of pERK1/2 in the nuclei or in aggregates at the perinuclear region of tumor cells.
Amsterdam A; Shezen E; Raanan C; Schreiber L; Slilat Y; Fabrikant Y; Melzer E; Seger R
Int J Oncol; 2012 Mar; 40(3):782-8. PubMed ID: 22108866
[TBL] [Abstract][Full Text] [Related]
3. Use of multiple biomarkers for the localization and characterization of colon cancer stem cells by indirect immunocytochemistry.
Amsterdam A; Raanan C; Schreiber L; Freyhan O; Fabrikant Y; Melzer E
Int J Oncol; 2012 Jul; 41(1):285-91. PubMed ID: 22504585
[TBL] [Abstract][Full Text] [Related]
4. [Correlation between the presence of Kras mutation and the presence of the proteins epiregulin and amphiregulin in colon cancer tissue].
Levi Y; Barshack I; Avivi K; Bar-ILan D; Gutman M; Aderka D; Berger R; Yacobi R
Harefuah; 2013 Jun; 152(6):326-9, 369. PubMed ID: 23885463
[TBL] [Abstract][Full Text] [Related]
5. [Molecular pathology - aspects in KRAS mutation analysis in colon carcinoma].
Hershkovitz D; Ben-lzhak O
Harefuah; 2013 Jun; 152(6):356-60, 367. PubMed ID: 23885470
[TBL] [Abstract][Full Text] [Related]
6. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
7. Correlation between the presence of KRAS mutation and the morphometric characteristics of colorectal carcinoma cell nuclei.
Greenberg A; Hershkovitz D; Sabo E
Anal Quant Cytopathol Histpathol; 2014 Feb; 36(1):23-31. PubMed ID: 24902368
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemistry using the BRAF V600E mutation-specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma.
Adackapara CA; Sholl LM; Barletta JA; Hornick JL
Histopathology; 2013 Aug; 63(2):187-93. PubMed ID: 23763264
[TBL] [Abstract][Full Text] [Related]
9. c-Met targeting enhances the effect of irradiation and chemical agents against malignant colon cells harboring a KRAS mutation.
Li Y; Wang J; Gao X; Han W; Zheng Y; Xu H; Zhang C; He Q; Zhang L; Li Z; Zhou D
PLoS One; 2014; 9(11):e113186. PubMed ID: 25427200
[TBL] [Abstract][Full Text] [Related]
10. Influence of anatomical subsite on the incidence of microsatellite instability, and KRAS and BRAF mutation rates in patients with colon carcinoma.
Benedix F; Meyer F; Kube R; Kropf S; Kuester D; Lippert H; Roessner A; Krüger S
Pathol Res Pract; 2012 Oct; 208(10):592-7. PubMed ID: 22898351
[TBL] [Abstract][Full Text] [Related]
11. Assessment of EGFR and KRAS mutation status from FNAs and core-needle biopsies of non-small cell lung cancer.
Lozano MD; Labiano T; Echeveste J; Gurpide A; Martín-Algarra S; Zhang G; Sharma A; Palma JF
Cancer Cytopathol; 2015 Apr; 123(4):230-6. PubMed ID: 25529460
[TBL] [Abstract][Full Text] [Related]
12. KRAS mutations in traditional serrated adenomas from Korea herald an aggressive phenotype.
Kim KM; Lee EJ; Kim YH; Chang DK; Odze RD
Am J Surg Pathol; 2010 May; 34(5):667-75. PubMed ID: 20305537
[TBL] [Abstract][Full Text] [Related]
13. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
Zhang X; Wang Y; Gao N; Wang J
Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565
[TBL] [Abstract][Full Text] [Related]
14. Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer.
Yen LC; Yeh YS; Chen CW; Wang HM; Tsai HL; Lu CY; Chang YT; Chu KS; Lin SR; Wang JY
Clin Cancer Res; 2009 Jul; 15(13):4508-13. PubMed ID: 19549774
[TBL] [Abstract][Full Text] [Related]
15. ACB-PCR quantification of K-RAS codon 12 GAT and GTT mutant fraction in colon tumor and non-tumor tissue.
Parsons BL; Marchant-Miros KE; Delongchamp RR; Verkler TL; Patterson TA; McKinzie PB; Kim LT
Cancer Invest; 2010 May; 28(4):364-75. PubMed ID: 20307197
[TBL] [Abstract][Full Text] [Related]
16. Differential response to EGFR- and VEGF-targeted therapies in patient-derived tumor tissue xenograft models of colon carcinoma and related metastases.
Jin K; Lan H; Cao F; Han N; Xu Z; Li G; He K; Teng L
Int J Oncol; 2012 Aug; 41(2):583-8. PubMed ID: 22581265
[TBL] [Abstract][Full Text] [Related]
17. KRAS mutant allele-specific imbalance (MASI) assessment in routine samples of patients with metastatic colorectal cancer.
Malapelle U; Sgariglia R; De Stefano A; Bellevicine C; Vigliar E; de Biase D; Sepe R; Pallante P; Carlomagno C; Tallini G; Troncone G
J Clin Pathol; 2015 Apr; 68(4):265-9. PubMed ID: 25609577
[TBL] [Abstract][Full Text] [Related]
18. Detection and recovery of circulating colon cancer cells using a dielectrophoresis-based device: KRAS mutation status in pure CTCs.
Fabbri F; Carloni S; Zoli W; Ulivi P; Gallerani G; Fici P; Chiadini E; Passardi A; Frassineti GL; Ragazzini A; Amadori D
Cancer Lett; 2013 Jul; 335(1):225-31. PubMed ID: 23419522
[TBL] [Abstract][Full Text] [Related]
19. Challenges posed to pathologists in the detection of KRAS mutations in colorectal cancers.
Dudley J; Tseng LH; Rooper L; Harris M; Haley L; Chen G; Gocke CD; Eshleman JR; Lin MT
Arch Pathol Lab Med; 2015 Feb; 139(2):211-8. PubMed ID: 25611103
[TBL] [Abstract][Full Text] [Related]
20. Adenoma and carcinoma components in colonic tumors show discordance for KRAS mutation.
Hershkovitz D; Simon E; Bick T; Prinz E; Noy S; Sabo E; Ben-Izhak O; Vieth M
Hum Pathol; 2014 Sep; 45(9):1866-71. PubMed ID: 24998492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
